XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics

What is the expected effect of the tender offer closing on XOMA's share price and trading volume? How does the valuation of the tender offer compare to Turnstone Biologics' recent market performance and peer transactions? What are the implications of the acquisition for XOMA's future royalty revenue streams and cash flow? Will the deal impact XOMA's capital structure, including debt levels or dilution of existing shareholders? How might this transaction affect XOMA's strategic positioning within the biotech and pharmaceutical royalty sector? Are there any regulatory or antitrust considerations that could delay or alter the completion of the merger? What is the market’s perception of XOMA’s ability to successfully integrate Turnstone Biologics’ assets and pipeline? How does this acquisition compare to recent similar deals in the industry in terms of premium paid and synergies expected? What potential risks could arise from the acquisition, such as integration challenges or unforeseen liabilities? Will the tender offer influence analyst coverage and earnings forecasts for XOMA in the upcoming quarters?